ChemoCentryx, Inc. (CCXI)

NASDAQ: CCXI · IEX Real-Time Price · USD
0.00 (0.00%)
At close: Sep 30, 2022 4:00 PM
-0.05 (-0.10%)
After-hours: Sep 30, 2022 7:54 PM EDT
Market Cap 3.72B
Revenue (ttm) 37.28M
Net Income (ttm) -133.09M
Shares Out 71.92M
EPS (ttm) -2.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 735,267
Open 51.67
Previous Close 51.66
Day's Range 51.66 - 51.79
52-Week Range 14.95 - 51.85
Beta 1.24
Analysts Hold
Price Target 53.04 (+2.7%)
Earnings Date Nov 7, 2022

About CCXI

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy... [Read more...]

Industry Biotechnology
IPO Date Feb 8, 2012
CEO Thomas Schall
Employees 178
Stock Exchange NASDAQ
Ticker Symbol CCXI
Full Company Profile

Financial Performance

In 2021, ChemoCentryx's revenue was $32.22 million, a decrease of -50.34% compared to the previous year's $64.89 million. Losses were -$131.76 million, 138.0% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for CCXI stock is "Hold." The 12-month stock price forecast is 53.04, which is an increase of 2.67% from the latest price.

Price Target
(2.67% upside)
Analyst Consensus: Hold
Stock Forecasts


Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year

The double-digit run for biotech stocks off a June bottom is great — until you realize you could've netted more by investing in the best. The post Here Are 10 Biotech Stocks — Including Catalyst And Vir...

1 week ago - Investors Business Daily

INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.'s Directors and Officers for Br...

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of C...

2 weeks ago - Business Wire

Cancer-Drug Maker's Solid Position And Successful Drug Record Drive Growth

Cancer-drug maker Amgen solidified its position in a highly competitive market by acquiring its rival Mirati Therapeutics.

3 weeks ago - Investors Business Daily

Why Is ChemoCentryx (CCXI) Up 1.4% Since Last Earnings Report?

ChemoCentryx (CCXI) reported earnings 30 days ago. What's next for the stock?

3 weeks ago - Zacks Investment Research


NEW YORK , Aug. 25, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches o...

Other symbols: AERIONEMSFT
1 month ago - PRNewsWire

ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences

SAN CARLOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned poster presentations at three upcoming medical conferences taking place in August and Se...

1 month ago - GlobeNewsWire

10 Stocks Driving the Biotech Resurgence

Barron's screened for stocks such as Global Blood Therapeutics and Karuna Therapeutics that popped this summer.

1 month ago - Barrons

Here's Why ChemoCentryx (CCXI) is a Great Momentum Stock to Buy

Does ChemoCentryx (CCXI) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 month ago - Zacks Investment Research

ChemoCentryx (CCXI) Now Trades Above Golden Cross: Time to Buy?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

1 month ago - Zacks Investment Research

Cramer tells investors to stay away from these two stocks

CNBC's Jim Cramer explained why investors should avoid purchasing shares of Boise Cascade and ChemoCentryx on Monday's episode of "Mad Money."

Other symbols: BCC
1 month ago - CNBC Television

Get ready for more merger mania in pharma sector the rest of the year

Pfizer Inc.'s PFE, +0.24% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, +0.02% is the latest sign that cash-flush drug makers are ready to jump back into dealmaking.

1 month ago - Market Watch

Shareholder Alert - The M&A Class Action Firm Announces the Investigation of ChemoCentryx, Inc. - CCXI

NEW YORK , Aug. 9, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated...

1 month ago - PRNewsWire

ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call

SAN CARLOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tues...

1 month ago - GlobeNewsWire

ChemoCentryx (CCXI) Moves 109.2% Higher: Will This Strength Last?

ChemoCentryx (CCXI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

1 month ago - Zacks Investment Research

ChemoCentrix Spikes 110% on Amgen Acquisition Deal

On Thursday, shares of ChemoCentryx Inc. ( CCXI , Financial) shot up more than 110% before closing the day at $50.43 on the news that the small-cap biotech company has entered into an agreement to be ac...

Other symbols: AMGN
1 month ago - GuruFocus

SHAREHOLDER ALERT: Weiss Law Investigates ChemoCentryx, Inc

NEW YORK, Aug. 4, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of ChemoCentryx, Inc. ("ChemoCentryx" or the "...

Other symbols: AMGN
1 month ago - PRNewsWire

Amgen Narrows Sales Outlook Following Plans To Acquire ChemoCentryx

Amgen narrowed its outlook for 2022 sales late Thursday after its second-quarter beat. But Amgen stock fell just a fraction.

Other symbols: AMGN
1 month ago - Investors Business Daily

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating ChemoCentryx, Inc. Buyout

Wilmington, Delaware--(Newsfile Corp. - August 4, 2022) - Rigrodsky Law, P.A. is investigating ChemoCentryx, Inc. ("ChemoCentryx") (NASDAQ: CCXI) regarding possible breaches of fiduciary duties and othe...

1 month ago - Newsfile Corp

ChemoCentryx Shares Are Jumping 110% Thursday: Here's Why

Shares of ChemoCentryx, Inc. (NASDAQ: CCXI) are skyrocketing Thursday following a groundbreaking announcement for the biopharmaceutical company. Why Is It Moving?

1 month ago - Benzinga

ChemoCentryx (CCXI) Stock Soars 100% on Amgen Acquisition

Source: Shutterstock ChemoCentryx (NASDAQ: CCXI ) stock is rocketing higher on Thursday as investors react to news of an acquisition deal with Amgen (NASDAQ: AMGN ). This deal has Amgen agreeing to acqu...

Other symbols: AMGN
1 month ago - InvestorPlace

Shareholder Alert: Ademi LLP investigates whether ChemoCentryx, Inc. has obtained a Fair Price in its transaction wit...

MILWAUKEE , Aug. 4, 2022 /PRNewswire/ -- Ademi LLP is investigating ChemoCentryx (NASDAQ: CCXI) for possible breaches of fiduciary duty and other violations of law in its transaction with Amgen.  Click ...

1 month ago - PRNewsWire

Why ChemoCentryx Stock Is On Fire Today

The rare-disease specialist is being bought out at a sizable premium.

1 month ago - The Motley Fool

Amgen Plans $3.7 Billion ChemoCentryx Buyout, Tapping Into A New Market

Amgen agreed to buy ChemoCentryx for $3.7 billion on Thursday, leading CCXI stock to rocket by a triple-digit percentage. The post Amgen Plans $3.7 Billion ChemoCentryx Buyout, Tapping Into A New Market...

Other symbols: AMGN
1 month ago - Investors Business Daily

CCXI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of ChemoCentryx, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of ChemoCentryx, Inc. (NASDAQ: CCXI) to Amgen Inc. for $52.00 per share in cash is fair to Che...

1 month ago - Business Wire

Amgen Acquires Drugmaker ChemoCentryx for $3.7 Billion

With the acquisition, the biotech company adds a newly approved drug for an autoimmune disorder.

Other symbols: AMGN
1 month ago - Barrons